Lawyers Reviewing Axiron Testosterone Gel Cases
The testosterone gel lawyers at Saiontz & Kirk, P.A. are investigating Axiron lawsuits on behalf of former users of the testosterone replacement therapy (TRT) throughout the United States who have suffered cardiovascular problems.
Contact Our Lawyers to Review a TESTOSTERONE INJURY CASE
Axiron is a newer testosterone treatment, which was introduced by Eli Lilly in 2010 as competitor for the widely used AndroGel testosterone.
Although it was marketed as a safe and effective treatment for low testosterone, side effects of Axiron may increase the risk that certain men suffer a:
- Heart Attack
- Blood Clot (Pulmonary Embolism or DVT)
- Sudden Death
As a result of Eli Lilly’s failure to adequately warn about the risk of injury associated with Axiron testosterone, financial compensation may be available for former users. To review a potential case for yourself or a loved one, request a free claim evaluation.
Axiron Testosterone Problems
Axiron is a gel that is applied under the arm via deodorant, which is designed to elevate low testosterone levels.
While it was originally approved for use among men suffering from testosterone deficiency caused by a medical condition, such as hypogonadism, Axiron and other testosterone treatments have been widely promoted for use among men who may not have any medical need for the hormone replacement therapy.
Axiron was introduced in 2010, amid growing popularity of AndroGel and other testosterone replacement treatments. Between 2000 and 2011, use of testosterone therapy increased five-fold, with sales for all treatments reaching $1.9 billion by 2012.
Eli Lilly sold Axiron as a superior alternative to AndroGel and other products, joining the market long after drug makers knew or should have known about the risk of serious and potentially life-threatening heart problems from testosterone treatments.
Did you or a family member work or live at Camp Lejeune or MCAS New River between 1953 – 1987? You may be eligible for a Camp Lejeune lawsuit.
In 2009, researchers halted a study involving testosterone treatments after discovering that men receiving the medications were experiencing higher rates of cardiac, respiratory and dermatologic events.
The results of this study were published in the New England Journal of Medicine in July 2010, raising the first concerns among consumers and the medical community about the risk of heart attacks from testosterone. However, information was available to drug manufacturers that could have discovered this risk much earlier.
Eli Lilly appears to have placed their desire for profits before consumer safety by failing to adequately and sufficiently research the potential Axiron side effects before joining the crowd of other drug makers aggressively marketing these treatments for low testosterone.
Through aggressive marketing, testosterone drug makers have promoted the products for users beyond the treatment of medical conditions they were designed for. As a result of direct-to-consumer advertisements that created terms like “Low T” and used other slogans designed to encourage otherwise healthy men to have their testosterone levels checked, it has been estimated that most men receiving testosterone replacement therapy have no medical need for the treatments.
The risk of Axiron testosterone gel problems was known, or should have been known, before this product was introduced to the market. As a result of their failure to warn consumers and the medical community, Eli Lilly was able to develop a prescription testosterone gel that quickly captured more than $300 million in annual sales.
Axiron Heart Attack, Stroke and Death Risk
Concerns about the link between Axiron and heart attacks was increased further in late 2013, when a study was published in the Journal of the American Medical Association (JAMA).
Researchers reviewed data involving 8,700 veterans with an average age of 60 who underwent a coronary angiography between 2005 and 2011. All of the men had low testosterone levels, yet those who received a testosterone gel, patch or injection prescription following the surgery were found to be 29% more likely to experience a heart attack, stroke or death.
That research was followed by a larger study published in the medical journal PLoS One in January 2014, which looked at data involving 55,593 men, including a large number of men under the age of 65.
Researchers found that younger men under the age of 65 who had a prior diagnosis of heart diesease may be twice as likely to suffer a non-fatal heart attack during the 90 days after they were first prescribed Axiron or another testosterone treatment. For men over the age of 65, the risk of heart attack was doubled, regardless of any pre-existing heart problems.
Following these studies, the FDA has launched an investigation into the potential health risks associated with Axiron, Androgel and other similar products. In addition, health experts and consumer advocacy groups have called for stronger testosterone warnings and for more careful selection of patients who may be candidates for the treatments.
Axiron Testosterone Class Action Lawyers
If Eli Lilly had provided sufficient warnings and information about the potential Axiron risks when the testosterone gel was introduced, men throughout the United States may have been able to avoid serious and potentially life-threatening heart problems.
As a result of the drug maker’s decision to place their desire for profits before consumer safety, potential Axiron class action lawsuits and individual injury cases are being reviewed for men who have suffered a heart attack, stroke, pulmonary embolism, deep vein thrombosis or other blood clot injury.
Potential Axiron wrongful death lawsuits are also being reviewed for family members of individuals who have died after using the testosterone gel.
All cases are reviewed by the Axiron testosterone gel lawyers at Saiontz & Kirk, P.A. under a contingency fee agreement, which means that there are no out-of-pocket expenses to hire our law firm and we receive no attorney fees or expenses unless a recovery is obtained.